These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 4579266)
1. [Molecular aspects of chemotherapy]. Drews J; Eich F; Högenauer G Verh Dtsch Ges Inn Med; 1972; 78():361-70. PubMed ID: 4579266 [No Abstract] [Full Text] [Related]
2. Effect of compounds with both antitumor and bacteriophage-inducing activities on Escherichia coli nucleic acid synthesis. Heinemann B; Howard AJ Antimicrob Agents Chemother (Bethesda); 1965; 5():488-92. PubMed ID: 5327520 [No Abstract] [Full Text] [Related]
4. Mechanism of action of showdomycin. V. Reduced ability of showdomycin-resistant mutants of Escherichia coli K-12 to take up showdomycin and nucleosides. Komatsu Y J Antibiot (Tokyo); 1971 Dec; 24(12):876-83. PubMed ID: 4946509 [No Abstract] [Full Text] [Related]
7. [Mutagenesis tests. The problem of antibiotics and chemotherapeutic agents]. Rodenghi F; Crippa M; Carniti G; Goldstein BP G Ital Chemioter; 1982; 29(1):15-9. PubMed ID: 6764432 [No Abstract] [Full Text] [Related]
8. The "sensitivity" of resting and dividing cells. Pittillo RF; Schabel FM; Skipper HE Klin Oczna; 1971; 41(5):137-42. PubMed ID: 5002845 [No Abstract] [Full Text] [Related]
9. [Chemotherapy for infectious diseases. Progress in the last several years]. Shimizu K Naika; 1967 Jun; 19(6):1011-6. PubMed ID: 4865493 [No Abstract] [Full Text] [Related]
10. [Effect of 5-fluorouracil on the transfer of the multiple drug resistance factor in bacteria]. Smolianskaia AZ Antibiotiki; 1970 Jan; 15(1):38-46. PubMed ID: 4909948 [No Abstract] [Full Text] [Related]
11. Optimal co-amoxiclav ratios for inhibiting Escherichia coli strains with different susceptibilities to the compounds. Gracia M; Ponte C; Soriano F Int J Antimicrob Agents; 2005 Apr; 25(4):352-3. PubMed ID: 15784320 [No Abstract] [Full Text] [Related]
12. Resistant Escherichia coli--we are what we eat. Collignon P Clin Infect Dis; 2009 Jul; 49(2):202-4. PubMed ID: 19508163 [No Abstract] [Full Text] [Related]
13. Studies on antitumor activity, antimicrobial activity and toxicity of phleomycin. Ishizuka M; Takayama H; Takeuchi T; Umezawa H J Antibiot (Tokyo); 1966 Nov; 19(6):260-71. PubMed ID: 4961685 [No Abstract] [Full Text] [Related]
14. Rise in ciprofloxacin resistance in Escherichia coli from urinary tract infections from 1999-2004. Barisić Z; Borzić E; Kraljević KS; Carev M; Zoranić V; Kaliterna V Int J Antimicrob Agents; 2005 Jun; 25(6):550-1. PubMed ID: 15878822 [No Abstract] [Full Text] [Related]
15. Increasing incidence of resistance of Escherichia coli to antimicrobials. Gedebou M; Tassew A Ethiop Med J; 1983 Apr; 21(2):61-9. PubMed ID: 6343076 [No Abstract] [Full Text] [Related]
16. Resistance to drugs and infectious drug resistance in Escherichia coli. Pinheiro LF; Barros AC; de Azevedo JL Hospital (Rio J); 1969 Nov; 76(5):1793-800. PubMed ID: 4906046 [No Abstract] [Full Text] [Related]
17. Infectious drug resistance in Thailand. II. Infectious drug resistance in Escherichia coli isolated from healthy adults and hospitalized patients in Bangkok. Koonkhamlert C; Sawyer WD J Med Assoc Thai; 1971 Nov; 54(11):794-803. PubMed ID: 4942858 [No Abstract] [Full Text] [Related]